Literature DB >> 16492439

Cystic fibrosis pulmonary exacerbations.

Thomas Ferkol1, Margaret Rosenfeld, Carlos E Milla.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492439     DOI: 10.1016/j.jpeds.2005.10.019

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  51 in total

1.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 2.  Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

Authors:  Bonnie W Ramsey
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

3.  Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

Authors:  A Clement; A Tamalet; E Leroux; S Ravilly; B Fauroux; J-P Jais
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

4.  Physical therapy management of a patient on portable extracorporeal membrane oxygenation as a bridge to lung transplantation: a case report.

Authors:  John D Lowman; Tamara K Kirk; Diane E Clark
Journal:  Cardiopulm Phys Ther J       Date:  2012-03

5.  The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.

Authors:  Catherine Norrish; Mark Norrish; Uwe Fass; Majid Al-Salmani; Ganji Shiva Lingam; Fiona Clark; Hebal Kallesh
Journal:  Oman Med J       Date:  2015-01

6.  Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis.

Authors:  Lyndia C Brumback; Arthur Baines; Felix Ratjen; Stephanie D Davis; Stephen L Daniel; Alexandra L Quittner; Margaret Rosenfeld
Journal:  Pediatr Pulmonol       Date:  2014-04-29

Review 7.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

8.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

9.  Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.

Authors:  Donald R VanDevanter; Mary A O'Riordan; Jeffrey L Blumer; Michael W Konstan
Journal:  Respir Res       Date:  2010-10-06

Review 10.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.